Physician profile
Robert Cacdac
NPI 1154950970
$5,118.30
in general payments reported to CMS, 2019-2025
16 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $983 · 2024: $1,580 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,833.58 |
| Education | $284.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,239.22 | 2025 | |
| Medtronic, INC. | $1,025.88 | 2023-2025 | Corevalve Evolut R |
| Biotronik INC. | $402.73 | 2024-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Actelion Pharmaceuticals US, INC. | $395.91 | 2024-2025 | Uptravi, Opsumit |
| Abbott Laboratories | $348.59 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Amgen INC. | $320.44 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $298.88 | 2024-2025 | Accolade Sr, Emblem Mri S-Icd, Watchman Flx |
| Pfizer INC. | $230.60 | 2024-2025 | |
| Edwards Lifesciences Corporation | $217.50 | 2025 | Evoque |
| Alnylam Pharmaceuticals INC. | $165.59 | 2025 | Onpattro, Amvuttra |
| Lexicon Pharmaceuticals, INC. | $147.50 | 2024 | Inpefa |
| United Therapeutics Corporation | $141.27 | 2024-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.05 | 2023 | |
| Merck Sharp & Dohme LLC | $27.40 | 2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $19.00 | 2024 | Wainua |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $15.74 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cacdac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.